1 Hypercholesterolæmi var rapporteret hos op til 5, 3% af patienter behandlet med rosiglitazon (monoterapi, dobbelt - eller tripelterapi).
1 Hypercholesterolaemia was reported in up to 5.3% of patients treated with rosiglitazone (monotherapy, dual or triple oral therapy).